Tenaya Therapeutics, Inc. (TNYA) Reports Q4 EPS of (12c), In Line with Consensus

NodeGuardian · 2026-03-24T06:28:08+00:00

Tenaya Therapeutics reported Q4 EPS of (12c), meeting expectations. CEO Faraz Ali noted progress in gene therapy programs TN-201 and TN-401, with updates expected in 2026. Positive preclinical data for TN-301 shows promise for Duchenne muscular dystrophy.

NodeGuardian

2026-03-24 06:28:08

Abstract generation in progress

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) reported Q4 EPS of (12c), matching the consensus estimate. CEO Faraz Ali highlighted clinical progress in 2025 and anticipates further updates in the first half of 2026 for its gene therapy programs TN-201 and TN-401. The company also presented positive preclinical data for its HDAC6 inhibitor, TN-301, showing improvements in Duchenne muscular dystrophy models.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.